PRESS-RELEASE ·Filed May 21, 2026
Press release · FDA
Actionable Insight • Neutral
Traders should monitor ASCO data release on June 2; positive results could drive significant upside given the $126M market cap and high unmet need, while negative data poses substantial downside risk. No action warranted until data is released.
Final — all horizons settled through T+60d
CRDF ▼ -50.22% at T+60d
NEUTRAL call -50.22% · α vs SPY -53.41% · entry $1.78 → $0.8861
T+1d
+8.99%
call +8.99% · α +8.40%
$1.94
settled 5mo ago
T+5d
-16.85%
call -16.85% · α -18.51%
$1.48
settled 5mo ago
T+20d
-26.69%
call -26.69% · α -25.27%
$1.31
settled 4mo ago
T+60d
-50.22%
call -50.22% · α -53.41%
$0.8861
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC at ASCO on June 2, 2026, followed by an investor webcast on June 3. No actual results were released today, making this a routine catalyst-date announcement.
Key Facts
- Updated data from the Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC will be presented at ASCO on June 2, 2026.
- An investor webcast is scheduled for June 3, 2026 to review the data.
- Previous data showed dose-dependent improvements in overall response rate and progression-free survival.
- The company has selected the 30 mg dose for a registrational trial.
Financial Impact
Not specified
Risk Factors
- Updated data may fail to meet prior expectations or show safety concerns.
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299771 |
18 reports for CRDF
73% Hit rate @ T+5 Went positive at some point 14 of 15 best @ T+60▲ +47.66%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8505 (+36.05%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8505 (−35.08%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8505 (+14.09%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8505 (−3.35%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8505 (+2.74%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8505 (+2.74%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8505 (−34.58%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8505 (+46.51%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8505 (−39.25%) |
Jun 2, 2026 20w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8505 (−43.68%) |
Showing 10 of 18
US Market Status
Market Open — Closes in 4h 3m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers